issues
July/August 2011
Download PDFTABLE OF CONTENTS
The New Phase I Entrepreneur
Derek G. Hennecke, MBA, continues with part 4 of his newest 6-part series on how not to blow the recovery!
Transdermal Delivery: Growing Rapidly With the Global Biologics Market
Contributor Cindy H. Dubin investigates the transdermal drug delivery market and discovers that not only are established players making great strides in novel systems, up-and-coming entrants plan on unique market introductions as they transition from topical to transdermal.
Adaptive Focused AcousticsTM for the Formulation of Suspensions & Nano-Suspensions
Srikanth Kakumanu, PhD, and James Bernhard describe how this scalable process produces suspensions that are more suitable over current methods for achieving better bioavailability and less variability in exposures resulting from a suspension with particle size reduction from a controlled, broadly applicable technique.
A Guide to Revenue Contract Management System Implementations: Avoid the Pitfalls & Optimize Your Opportunities
James Burke and Richard Butler indicate that by taking the time early in the process to establish a disciplined, informed, and forward-thinking implementation approach to the key areas discussed in this article, you can mitigate the associated risks and deliver a successful solution that ultimately meets your financial and business objectives.
Advanced Adhesive Technologies Deliver Enhanced Performance Capabilities to Transdermal Product Designs
Jeffrey Purnell, PhD, explains how new adhesive and polymer technologies will improve the patient experience for wear and comfort, and introduces emerging technologies that will deliver enhanced capabilities for the next generation of transdermal controlled-release applications.
TYRX: Combination Drug-Device Products That Help Prevent Surgical Infections Associated With Implanted Medical Devices
Drug Development Executive: Robert White, President and CEO of TYRX, discusses his company’s proprietary technology and products as well as the market outlook for such drug-device combinations.
Biosimilars: Pathway Still Unclear
Industry Analyst Katheryn Symank says according to IMS Health, biopharmaceuticals collectively generated sales of $130 billion globally in 2009, and as demand for these expensive and often life-saving medications increases, so does the interest in making less-expensive biosimilars available to Americans.
The Zeta Potential & its Use in Pharmaceutical Applications – Part 1: Charged Interfaces in Polar & Non-Polar Media & the Concept of the Zeta Potential
David Fairhurst, PhD, and Robert W. Lee, PhD, review, in part one of a two-part article, the concept of Zeta Potential and discuss the physicomechanical and physicochemical properties that govern it in both polar and non-polar systems.
Neurodegeneration in Multiple Sclerosis: A Target for a Novel Therapeutic Approach
Getaw Worku Hassen, MD, PhD; Leo Kesner, PhD; and Alfred Stracher, PhD; review the role of proteases and protease inhibitors as a therapeutic option for the treatment of MS.
Eyetech Inc.: Employee-Owned Biotech Dedicated Exclusively to Retinal Diseases
Executive Summary: Steven Bettis, President and Co-Founder of Eyetech, discusses his company’s remarkable inception, ongoing efforts to improve the administration of Macugen, and how the treatment landscape of retinal diseases is changing for the better.
DEPARTMENTS
Market News & Trends
Excipient Update
Reviewing Thaumatin’s Pharmaceutical Applications
Advanced Delivery Devices
Delivering Quality in Personal Dosimetry Devices
Technology & Services Showcase
External Delivery
Crunch Time: Obtaining the Financial Commitment
COVER
FEATURES
